eric
04-14-2004, 08:44 AM
Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) announced today the initiation of a Phase I Clinical Trial in cancer to assess the safety and tolerability of intravenous VEGF Trap. The study is being conducted in collaboration with Aventis Regeneron’s partner in the development of the VEGF Trap in oncology and eye disorders.
“The FDA’s recent approval of the first angiogenesis inhibitor to treat cancer not only validates the approach but also encourages the development of other anti-angiogenesis agents such as the VEGF Trap that may be more effective “ noted Leonard S. Schleifer M.D. Ph. D. President and Chief Executive Officer of Regeneron. “Our preclinical research shows that the VEGF Trap is perhaps the most potent blocker of VEGF described and may play a role in treating an array of diseases including cancer in which the growth of new blood vessels is an important contributor to the disease process.�
http://news.scotsman.com/latest.cfm?id=2779721
“The FDA’s recent approval of the first angiogenesis inhibitor to treat cancer not only validates the approach but also encourages the development of other anti-angiogenesis agents such as the VEGF Trap that may be more effective “ noted Leonard S. Schleifer M.D. Ph. D. President and Chief Executive Officer of Regeneron. “Our preclinical research shows that the VEGF Trap is perhaps the most potent blocker of VEGF described and may play a role in treating an array of diseases including cancer in which the growth of new blood vessels is an important contributor to the disease process.�
http://news.scotsman.com/latest.cfm?id=2779721